Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow-up analysis of the Copenhagen City Heart Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus : A follow-up analysis of the Copenhagen City Heart Study. / Ozbek, Burcu Tas; Modin, Daniel; Mogelvang, Rasmus; Jorgensen, Peter Godsk; Jensen, Magnus Thorsten; Schnohr, Peter; Gislason, Gunnar Hilmar; Biering-Sorensen, Tor.

I: Diabetic Medicine, Bind 38, Nr. 10, 14627, 2021.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Ozbek, BT, Modin, D, Mogelvang, R, Jorgensen, PG, Jensen, MT, Schnohr, P, Gislason, GH & Biering-Sorensen, T 2021, 'Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow-up analysis of the Copenhagen City Heart Study', Diabetic Medicine, bind 38, nr. 10, 14627. https://doi.org/10.1111/dme.14627

APA

Ozbek, B. T., Modin, D., Mogelvang, R., Jorgensen, P. G., Jensen, M. T., Schnohr, P., Gislason, G. H., & Biering-Sorensen, T. (2021). Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow-up analysis of the Copenhagen City Heart Study. Diabetic Medicine, 38(10), [14627]. https://doi.org/10.1111/dme.14627

Vancouver

Ozbek BT, Modin D, Mogelvang R, Jorgensen PG, Jensen MT, Schnohr P o.a. Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow-up analysis of the Copenhagen City Heart Study. Diabetic Medicine. 2021;38(10). 14627. https://doi.org/10.1111/dme.14627

Author

Ozbek, Burcu Tas ; Modin, Daniel ; Mogelvang, Rasmus ; Jorgensen, Peter Godsk ; Jensen, Magnus Thorsten ; Schnohr, Peter ; Gislason, Gunnar Hilmar ; Biering-Sorensen, Tor. / Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus : A follow-up analysis of the Copenhagen City Heart Study. I: Diabetic Medicine. 2021 ; Bind 38, Nr. 10.

Bibtex

@article{d9275727a61f466d862e3b20414d7221,
title = "Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus: A follow-up analysis of the Copenhagen City Heart Study",
abstract = "Background Previous studies have identified several echocardiographic markers of cardiac dysfunction in participants with diabetes mellitus, including E/e'. However, previous studies have been limited by short follow-up duration or low statistical power, and none have assessed whether echocardiographic predictors of adverse cardiovascular outcome differ between individuals with DM and individuals without DM. Methods A total of 1997 individuals from the general population without heart disease had an echocardiogram performed in 2001 to 2003. Diabetes was defined as HbA(1c) >= 6.5% (>= 48 mmol/mol), non-fasted blood glucose >= 11.1 mmol/L or the use of glucose lowering medication. The end-point was a composite of heart failure (HF), ischemic heart disease (IHD) and cardiovascular death (CVD). Results At baseline, a total of 292 participants (15%) had diabetes. Median follow-up time was 12.4 years (interquartile-range: 9.8-12.8 years) and follow-up was 100%. During follow-up, 101 participants (35%) with diabetes and 281 participants without diabetes (16%) reached the composite end-point. The prognostic value of E/e' was significantly modified by diabetes (p for interaction: 0.003). In participants with diabetes, only E/e' remained an independent predictor of outcome in a final multivariable model adjusted for clinical and echocardiographic parameters (HR 1.08, 95% CI 1.00-1.17, p = 0.0041, per 1 increase). In participants without diabetes, left ventricular mass index (LVMI), left ventricular ejection fraction (LVEF) and a' remained independent predictors of outcome when adjusted for clinical and echocardiographic parameters. In individuals with diabetes, only E/e' added incremental prognostic value to risk factors from the SCORE risk chart and the ACC/AHA Pooled Cohort Equation. Conclusion In individuals with diabetes from the general population, E/e' is a stronger predictor of cardiovascular mortality and morbidity than in individuals without diabetes and contributes with incremental prognostic value in addition to established cardiovascular risk factors.",
keywords = "cardiology, echo, imaging, type 1 diabetes, type 2 diabetes, IMAGING M-MODE, DIASTOLIC DYSFUNCTION, EUROPEAN-ASSOCIATION, AMERICAN-SOCIETY, PROGNOSTIC VALUE, UPDATE, RISK, RECOMMENDATIONS, GUIDELINES, MORTALITY",
author = "Ozbek, {Burcu Tas} and Daniel Modin and Rasmus Mogelvang and Jorgensen, {Peter Godsk} and Jensen, {Magnus Thorsten} and Peter Schnohr and Gislason, {Gunnar Hilmar} and Tor Biering-Sorensen",
year = "2021",
doi = "10.1111/dme.14627",
language = "English",
volume = "38",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Echocardiographic predictors of long-term adverse cardiovascular outcomes in participants with and without diabetes mellitus

T2 - A follow-up analysis of the Copenhagen City Heart Study

AU - Ozbek, Burcu Tas

AU - Modin, Daniel

AU - Mogelvang, Rasmus

AU - Jorgensen, Peter Godsk

AU - Jensen, Magnus Thorsten

AU - Schnohr, Peter

AU - Gislason, Gunnar Hilmar

AU - Biering-Sorensen, Tor

PY - 2021

Y1 - 2021

N2 - Background Previous studies have identified several echocardiographic markers of cardiac dysfunction in participants with diabetes mellitus, including E/e'. However, previous studies have been limited by short follow-up duration or low statistical power, and none have assessed whether echocardiographic predictors of adverse cardiovascular outcome differ between individuals with DM and individuals without DM. Methods A total of 1997 individuals from the general population without heart disease had an echocardiogram performed in 2001 to 2003. Diabetes was defined as HbA(1c) >= 6.5% (>= 48 mmol/mol), non-fasted blood glucose >= 11.1 mmol/L or the use of glucose lowering medication. The end-point was a composite of heart failure (HF), ischemic heart disease (IHD) and cardiovascular death (CVD). Results At baseline, a total of 292 participants (15%) had diabetes. Median follow-up time was 12.4 years (interquartile-range: 9.8-12.8 years) and follow-up was 100%. During follow-up, 101 participants (35%) with diabetes and 281 participants without diabetes (16%) reached the composite end-point. The prognostic value of E/e' was significantly modified by diabetes (p for interaction: 0.003). In participants with diabetes, only E/e' remained an independent predictor of outcome in a final multivariable model adjusted for clinical and echocardiographic parameters (HR 1.08, 95% CI 1.00-1.17, p = 0.0041, per 1 increase). In participants without diabetes, left ventricular mass index (LVMI), left ventricular ejection fraction (LVEF) and a' remained independent predictors of outcome when adjusted for clinical and echocardiographic parameters. In individuals with diabetes, only E/e' added incremental prognostic value to risk factors from the SCORE risk chart and the ACC/AHA Pooled Cohort Equation. Conclusion In individuals with diabetes from the general population, E/e' is a stronger predictor of cardiovascular mortality and morbidity than in individuals without diabetes and contributes with incremental prognostic value in addition to established cardiovascular risk factors.

AB - Background Previous studies have identified several echocardiographic markers of cardiac dysfunction in participants with diabetes mellitus, including E/e'. However, previous studies have been limited by short follow-up duration or low statistical power, and none have assessed whether echocardiographic predictors of adverse cardiovascular outcome differ between individuals with DM and individuals without DM. Methods A total of 1997 individuals from the general population without heart disease had an echocardiogram performed in 2001 to 2003. Diabetes was defined as HbA(1c) >= 6.5% (>= 48 mmol/mol), non-fasted blood glucose >= 11.1 mmol/L or the use of glucose lowering medication. The end-point was a composite of heart failure (HF), ischemic heart disease (IHD) and cardiovascular death (CVD). Results At baseline, a total of 292 participants (15%) had diabetes. Median follow-up time was 12.4 years (interquartile-range: 9.8-12.8 years) and follow-up was 100%. During follow-up, 101 participants (35%) with diabetes and 281 participants without diabetes (16%) reached the composite end-point. The prognostic value of E/e' was significantly modified by diabetes (p for interaction: 0.003). In participants with diabetes, only E/e' remained an independent predictor of outcome in a final multivariable model adjusted for clinical and echocardiographic parameters (HR 1.08, 95% CI 1.00-1.17, p = 0.0041, per 1 increase). In participants without diabetes, left ventricular mass index (LVMI), left ventricular ejection fraction (LVEF) and a' remained independent predictors of outcome when adjusted for clinical and echocardiographic parameters. In individuals with diabetes, only E/e' added incremental prognostic value to risk factors from the SCORE risk chart and the ACC/AHA Pooled Cohort Equation. Conclusion In individuals with diabetes from the general population, E/e' is a stronger predictor of cardiovascular mortality and morbidity than in individuals without diabetes and contributes with incremental prognostic value in addition to established cardiovascular risk factors.

KW - cardiology

KW - echo

KW - imaging

KW - type 1 diabetes

KW - type 2 diabetes

KW - IMAGING M-MODE

KW - DIASTOLIC DYSFUNCTION

KW - EUROPEAN-ASSOCIATION

KW - AMERICAN-SOCIETY

KW - PROGNOSTIC VALUE

KW - UPDATE

KW - RISK

KW - RECOMMENDATIONS

KW - GUIDELINES

KW - MORTALITY

U2 - 10.1111/dme.14627

DO - 10.1111/dme.14627

M3 - Journal article

C2 - 34153131

VL - 38

JO - Diabetic Medicine

JF - Diabetic Medicine

SN - 0742-3071

IS - 10

M1 - 14627

ER -

ID: 274429974